Trial Profile
Phase II clinical trial, multicenter, open, uncontrolled, to evaluate the effectiveness of the combination of sorafenib and bevacizumab in the treatment of patients with advanced and/or metastatic neuroendocrine tumors [ENSAYO CLINICO DE FASE II, MULTICENTRICO, ABIERTO, NO CONTROLADO PARA EVALUAR LA EFICACIA DE LA COMBINACION DE SORAFENIB Y BEVACIZUMAB EN EL TRATAMIENTO DE PACIENTES CON TUMOR NEUROENDOCRINO AVANZADO Y/O METASTASICO]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Sorafenib (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- Acronyms GETNE0801
- 23 Apr 2023 Results pooled analysis from SU11248, SUN1111), Pazopanib (PAZONET), sorafenib-bevacizumab (GETNE0801) and Lenvatinib (TALENT) published in the European Journal of Cancer
- 24 Aug 2011 New trial record
- 01 Sep 2009 Status changed from recruiting to completed according to results published in the European Journal of Cancer.